4 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 5 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow Supratentorial Glioblastoma: new trials by email Literature Review of Supratentorial Glioblastoma trials Research Report on Supratentorial Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) P140K-MGMT, O6-benzylguanine, Photon Based Radiotherapy - Glioblastoma Multiforme, Glioblastoma Multiforme, Adult | Phase 2 | Recruiting | Leland Metheny | 16 | 2023-01-20 | 2026-09-10 |
| LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma lerapolturev, pembrolizumab - Glioblastoma, Recurrent Glioblastoma | Phase 2 | Completed | Istari Oncology, Inc. | 25 | 2020-10-21 | 2025-06-05 |
| Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma Extended Release Flucytosine, NovoTTF-100A Device, Quality-of-Life Assessment - Anaplastic Astrocytoma, Glioblastoma | Phase 2 / Phase 3 | Withdrawn | NRG Oncology | 2020-01-31 | 2026-05-07 | |
| Prognostic Impact of Surgical Resection Extent for Supratentorial High Grade Gliomas. Supratentorial high grade gliomas resection. - Supratentorial Glioblastoma | Unknown | Assiut University | 28 | 2019-09-01 | 2019-08-07 | |
| 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma Fludeoxyglucose F-18, Osimertinib, Positron Emission Tomography - EGFR Gene Amplification, EGFR Gene Mutation | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 12 | 2018-11-28 | 2024-11-12 |
| Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab - Glioblastoma, Gliosarcoma | Phase 2 | Active not recruiting | Mayo Clinic | 52 | 2018-01-15 | 2026-09-22 |
| Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Gliosarcoma, Supratentorial Glioblastoma | Phase 1 | Completed | National Cancer Institute (NCI) | 32 | 2015-04-16 | 2023-01-10 |
| Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy Mefloquine, Memantine Hydrochloride, Metformin Hydrochloride - Glioblastoma, Gliosarcoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 144 | 2011-09-14 | 2025-05-07 |
| Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma 3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy - Glioblastoma, Gliosarcoma | Phase 3 | Completed | National Cancer Institute (NCI) | 637 | 2009-04-15 | 2019-07-24 |
Glioblastoma (7) · Gliosarcoma (4) · Astrocytoma (1) · Brain Neoplasms (1) · Oligodendroglioma (1)
Glioma (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Germ Cell and Embryonal (8) · Neoplasms, Glandular and Epithelial (8) · Neoplasms, Nerve Tissue (8) · Neoplasms, Neuroepithelial (8) · Neuroectodermal Tumors (8) · Astrocytoma (6) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Temozolomide (6) · Radiation (2) · Radiotherapy (2) · pembrolizumab (2) · Bevacizumab (1) · CTLA-4 Antigen (1) · Carmustine (1) · DNA (1) · Disulfides (1) · Filgrastim (1) · Fluorodeoxyglucose F18 (1) · Immunoglobulin G (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Mefloquine (1)
National Cancer Institute (NCI) (2) · Assiut University (1) · Istari Oncology, Inc. (1) · Jonsson Comprehensive Cancer Center (1) · Leland Metheny (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1)
United States (7) · Canada (1) · Israel (1)
Ian F. Parney, MD, PhD (1) · Leland Metheny, MD (1) · Lisa Franklin (1) · Mahmoud Ragab (1) · Manmeet S Ahluwalia (1) · Mark Gilbert (1) · Mark R Gilbert (1) · Timothy Cloughesy (1) · Vinay Puduvalli (1)
PMID 24552317, PMID 29490632, PMID 38874333
U10CA180868 (3), U01CA236215 (1), U10CA021661 (1)